HC Wainwright Lowers Savara (NASDAQ:SVRA) Price Target to $6.00

Savara (NASDAQ:SVRA) had its price objective decreased by HC Wainwright from $10.00 to $6.00 in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Several other analysts have also recently weighed in on SVRA. Evercore ISI reissued an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Savara has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Price Performance

Shares of SVRA opened at $2.98 on Wednesday. The firm has a market capitalization of $511.43 million, a PE ratio of -6.93 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 11.31. The company’s 50-day moving average is $3.88 and its 200-day moving average is $4.19. Savara has a fifty-two week low of $2.83 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Equities analysts forecast that Savara will post -0.44 EPS for the current year.

Institutional Trading of Savara

Large investors have recently modified their holdings of the stock. ProShare Advisors LLC lifted its position in Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after buying an additional 3,706 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Savara by 14.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after buying an additional 5,335 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Savara by 5.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after acquiring an additional 6,141 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.